Skip to Content
Morningstar
Get 14 Days Free

Icon PLC ICLR

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Icon Reports Healthy Q2 and Stronger 2021 Guidance After PRA Deal Closes; Raising FVE to $185

Rachel Elfman Equity Analyst

Analyst Note

| Rachel Elfman |

Icon reported second-quarter revenue of $871 million, representing over a 40% increase from the prior-year period. The company has completed its acquisition of PRA Health Sciences, and management announced an updated 2021 outlook with revenue guidance of $5.3 billion-$5.5 billion for the combined company. Due to the improved outlook for the year and greater synergies from the acquisition, we’ve increased our fair value estimate to $185 per share from $173. Our narrow moat and stable moat trend ratings are unchanged.

Read Full Analysis

Company Profile

Business Description

Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.

Contact
South County Business Park, Leopardstown
Dublin, 18, Ireland
T +353 12912000
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Jun 30, 2021
Fiscal Year End Dec 31, 2020
Stock Type —
Employees 38,000

Related

Stock Strategist Industry Reports
CROs Poised to Benefit From Biopharma Outsourcing
Of the contract research organizations we cover, Syneos looks most attractively valued.
Anna Baran
Fund Spy: Morningstar Medalist Edition
The Best and Worst Medalists of 2015's First Quarter
Small growth and biotech exposure led, while large value lagged.
Dan Culloton
Stock Strategist
A Shift in Health-Care M&A Activity
Recent deals have been driven more by tax strategies than therapeutic synergies.
Basili Alukos
US Videos
This Undervalued Stock May Be Just What the Doctor Ordered
With Big Pharma shifting its drug development toward a strategic-partnership model, wide-moat Icon PLC's scale makes it one of the few companies capable of bidding on and winning these new contracts.
David Krempa
US Videos
No Medicine Needed for These Moat Stocks
Several CROs are undervalued at current prices, have positive moat trends, and possess key characteristics to rise above the pack, say Morningstar's Matt Coffina and David Krempa.
Matthew Coffina
Stock Strategist Industry Reports
Late-Stage Businesses Drive Narrow Moats for CROs
The top contract research organizations have opportunities to gain share in a rapidly growing industry.
David Krempa
Investing Specialists
Wide Moats, Positive Moat Trends, Exemplary Stewardship
Morningstar StockInvestor editor Matt Coffina highlights three of the highest-quality companies we cover.
Matthew Coffina
Quarter-End Insights
Our Outlook for Health-Care Stocks
With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.
Alex Morozov

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.